Please provide your email address to receive an email when new articles are posted on . Once-daily linaclotide improved weekly spontaneous bowel movements from 1.16 to 3.41 during the 12-week ...
– The earliest licensed entry of any generic linaclotide 72 mcg, 145 mcg or 290 mcg in the U.S. is March 2029 – BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), announced today ...
Hosted on MSN
FDA approves Linzess (Linaclotide) for kids 7+ with IBS-C: First-ever treatment for pediatric constipation pain
The FDA just approved a new medication called Linzess (linaclotide) for kids aged 7 and older who have irritable bowel syndrome with constipation (IBS-C). This is a big deal because until now, there ...
There are no known causes and usually multiple factors leading to the common condition that makes stools hard and difficult to pass, according to the FDA. Linzess was approved in 2012 for adult ...
The FINANCIAL — Astellas Pharma Inc. announced that it launched a guanylate cyclase-C (GC-C) receptor agonist, LINZESS Tablets for irritable bowel syndrome with constipation) (“IBS-C”) in Japan on ...
Credit: Shutterstock. Linzess is a guanylate cyclase-C agonist. The Food and Drug Administration (FDA) has approved Linzess ® (linaclotide) for the treatment of functional constipation (FC) in ...
The US Food and Drug Administration (FDA) has expanded the indication for linaclotide (Linzess) to children as young as age 6 years with functional constipation, making it the first approved treatment ...
If approved, linaclotide would be the first prescription therapy for functional constipation in children and adolescents 6 to 17 years of age 1 Submission is based on positive Phase 3 study data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results